Clinical trial
A Phase IIIb Study of Durvalumab as Consolidation Treatment for Patients Diagnosed With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Definitive Concurrent or Sequential Platinum-based Chemoradiation Therapy in Spain (ALBORAN).
NCT06992609 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIIb Study of Durvalumab as Consolidation Treatment for Patients Diagnosed With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Definitive Concurrent or Sequential Platinum-based Chemoradiation Therapy in Spain (ALBORAN).
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 15, 2025
- Completion date
- June 30, 2029
- Enrollment
- 68 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.